
Results
78
78 companies
Intellia Therapeutics
Market Cap: US$2.2b
Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
NTLA
US$15.67
7D
29.4%
1Y
70.3%
Dianthus Therapeutics
Market Cap: US$4.5b
A clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
DNTH
US$82.49
7D
0.5%
1Y
389.4%
Vaxcyte
Market Cap: US$7.4b
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
PCVX
US$51.44
7D
8.4%
1Y
56.5%
Exelixis
Market Cap: US$13.0b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$51.91
7D
-2.3%
1Y
28.6%
ACADIA Pharmaceuticals
Market Cap: US$3.7b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$21.62
7D
2.5%
1Y
-4.8%
Biogen
Market Cap: US$29.0b
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
BIIB
US$196.58
7D
-1.7%
1Y
54.7%
Corcept Therapeutics
Market Cap: US$8.6b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$79.91
7D
-3.6%
1Y
12.0%
Stevanato Group
Market Cap: US$4.8b
Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
STVN
US$17.54
7D
2.7%
1Y
-24.7%
Trevi Therapeutics
Market Cap: US$2.4b
A clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
TRVI
US$17.21
7D
21.1%
1Y
188.8%
Regeneron Pharmaceuticals
Market Cap: US$62.1b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
REGN
US$609.94
7D
-0.4%
1Y
19.7%
United Therapeutics
Market Cap: US$22.8b
Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
UTHR
US$536.59
7D
-1.7%
1Y
84.6%
IDEAYA Biosciences
Market Cap: US$2.7b
A precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
IDYA
US$31.23
7D
7.8%
1Y
44.1%
Catalyst Pharmaceuticals
Market Cap: US$3.8b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$31.38
7D
0.06%
1Y
39.6%
Structure Therapeutics
Market Cap: US$3.2b
A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
GPCR
US$44.51
7D
3.7%
1Y
104.8%
Kiniksa Pharmaceuticals International
Market Cap: US$4.2b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$55.11
7D
6.2%
1Y
93.8%
Hisamitsu Pharmaceutical
Market Cap: US$8.2b
Manufactures and sells pharmaceuticals in Japan.
HTSU.Y
US$4.55
7D
0%
1Y
n/a
Supernus Pharmaceuticals
Market Cap: US$2.6b
A biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
SUPN
US$44.38
7D
-0.07%
1Y
37.5%
GRAIL
Market Cap: US$2.7b
A commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
GRAL
US$63.74
7D
6.5%
1Y
39.7%
Agilent Technologies
Market Cap: US$35.9b
Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
A
US$127.06
7D
-2.1%
1Y
10.0%
Enliven Therapeutics
Market Cap: US$2.7b
A clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
ELVN
US$45.10
7D
-2.2%
1Y
111.7%
Incyte
Market Cap: US$19.6b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$98.22
7D
-9.5%
1Y
43.5%
Spyre Therapeutics
Market Cap: US$7.7b
A clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
SYRE
US$88.34
7D
9.3%
1Y
488.5%
Neurocrine Biosciences
Market Cap: US$15.9b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$158.29
7D
-0.9%
1Y
25.1%
Bio-Techne
Market Cap: US$9.1b
Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
TECH
US$57.94
7D
7.3%
1Y
16.1%
Apogee Therapeutics
Market Cap: US$6.8b
A clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.
APGE
US$90.38
7D
2.3%
1Y
115.4%
Krystal Biotech
Market Cap: US$10.3b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$348.06
7D
9.5%
1Y
162.8%
Vericel
Market Cap: US$2.0b
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
VCEL
US$40.10
7D
7.0%
1Y
-4.6%
MBX Biosciences
Market Cap: US$2.0b
A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
MBX
US$43.03
7D
21.2%
1Y
341.8%
Roivant Sciences
Market Cap: US$22.6b
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
ROIV
US$31.43
7D
4.6%
1Y
174.5%
Celldex Therapeutics
Market Cap: US$2.5b
A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
CLDX
US$32.43
7D
3.7%
1Y
58.2%
Tango Therapeutics
Market Cap: US$4.0b
A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
TNGX
US$27.97
7D
-9.6%
1Y
442.1%
Viking Therapeutics
Market Cap: US$3.5b
A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
VKTX
US$30.38
7D
5.7%
1Y
16.8%
Nektar Therapeutics
Market Cap: US$2.1b
A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
NKTR
US$60.98
7D
2.7%
1Y
616.6%
Oruka Therapeutics
Market Cap: US$4.4b
A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
ORKA
US$72.34
7D
3.5%
1Y
519.3%
Immunome
Market Cap: US$2.1b
A biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
IMNM
US$18.74
7D
2.0%
1Y
114.2%
Kailera Therapeutics
Market Cap: US$2.6b
Operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
KLRA
US$19.90
7D
5.3%
1Y
n/a